A Phase II study to assess the safety and efficacy of TGR-1202 in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
A study for patients with chronic lymphocytic leukemia (CLL) using study drug TDR-1202
Sponsor: TG Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAQ8698
U.S. Govt. ID: NCT02742090
Contact: Nicole Lamanna: 646-317-5205 / nl2129@cumc.columbia.edu
Additional Study Information: This study is being done to see how well tolerated the investigational drug TGR-1202 is in comparison to other similar therapeutics agents in treating patients with chronic lymphocytic leukemia (CLL).
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Do you have a confirmed diagnosis of CLL? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Nicole Lamanna
nl2129@cumc.columbia.edu
646-317-5205
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE